Drovix — Institutional principal counterparty — aggregated bilateral OTC liquidity
A young but unusually well-documented LP. The licence is a genuine tier-2 authorisation stated without inflation, the engineering claims are specific enough to be held to, and the disclosure of what the firm is NOT is cleaner than most tier-1 brands manage. Entry point for counterparties: sandbox first, scale on measured results.